US 11,998,521 B2
Use of an RXR agonist in treating drug resistant HER2+ cancers
Martin E. Sanders, Spring, TX (US); Powel H. Brown, Houston, TX (US); Cassandra Moyer, Houston, TX (US); and Abhijit Mazumdar, Houston, TX (US)
Assigned to Io Therapeutics, Inc., Spring, TX (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Io Therapeutics, Inc., Spring, TX (US); and Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Dec. 7, 2022, as Appl. No. 18/076,997.
Claims priority of provisional application 63/286,981, filed on Dec. 7, 2021.
Prior Publication US 2023/0172890 A1, Jun. 8, 2023
Int. Cl. A61K 31/216 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/32 (2006.01)
CPC A61K 31/216 (2013.01) [A61P 35/00 (2018.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method of treating a patient with Her2+ cancer resistant to at least one Her2-targeted therapeutic agent, the method comprising administering a retinoid X receptor (RXR) agonist of Formula I

OG Complex Work Unit Chemistry
wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, to the patient;
wherein the Her2+ cancer resistant to a Her2-targeted therapeutic agent is also resistant to the RXR agonist of Formula I; and
the patient has received or is receiving the Her2-targeted therapeutic agent.